Amedisys Q2 EPS $1.32 Beats $1.18 Estimate, Sales $591.19M Beat $578.82M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amedisys (NASDAQ:AMED) reported Q2 earnings per share (EPS) of $1.32, beating the analyst estimate of $1.18. Sales were $591.19 million, surpassing the $578.82 million estimate. Despite a year-over-year EPS decrease, sales increased by 6.91%.
July 24, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amedisys reported Q2 EPS of $1.32, beating estimates by 11.86%. Sales were $591.19 million, exceeding estimates by 2.14%. Despite a slight year-over-year EPS decrease, sales increased by 6.91%.
Amedisys' Q2 earnings and sales both exceeded analyst estimates, which is generally positive for the stock price. The year-over-year sales increase further supports a positive outlook, despite a slight decrease in EPS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100